Dashboard
Manage Tickers

SLNO SOLENO THERAPEUTICS INC

Nasdaq soleno.life


$ 65.99 $ 1.68 (2.57 %)    

Tuesday, 21-Oct-2025 17:53:16 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 610.29 $ -0.16 (-0.03 %)
DIA $ 469.10 $ 2.20 (0.47 %)
SPY $ 670.98 $ -0.01 (0 %)
TLT $ 91.99 $ 0.45 (0.49 %)
GLD $ 376.61 $ -25.91 (-6.43 %)
$ 67.13
$ 65.44
$ 65.90 x 10
$ 68.03 x 7
$ 64.20 - $ 67.50
$ 41.50 - $ 90.32
1,232,939
na
3.57B
$ 3.34
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 02-28-2025 01-01-1970 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-07-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-22-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-10-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-31-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 07-28-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 03-03-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-12-2020 03-31-2020 10-Q
23 03-04-2020 12-31-2019 10-K
24 11-13-2019 09-30-2019 10-Q
25 08-07-2019 06-30-2019 10-Q
26 05-13-2019 03-31-2019 10-Q
27 03-20-2019 12-31-2018 10-K
28 11-14-2018 09-30-2018 10-Q
29 08-14-2018 06-30-2018 10-Q
30 05-15-2018 03-31-2018 10-Q
31 04-02-2018 12-31-2017 10-K
32 11-14-2017 09-30-2017 10-Q
33 08-11-2017 06-30-2017 10-Q
34 05-11-2017 03-31-2017 10-Q
35 03-15-2017 12-31-2016 10-K
36 11-14-2016 09-30-2016 10-Q
37 08-12-2016 06-30-2016 10-Q
38 05-12-2016 03-31-2016 10-Q
39 03-25-2016 12-31-2015 10-K
40 11-12-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
10 Health Care Stocks Whale Activity In To...
10/08/2025 17:35:32

acadia-pharma-faces-trial-setback-as-prader-willi-syndrome-trial-falls-short
Acadia Pharma Faces Trial Setback As Prade...
09/24/2025 14:05:05

Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/24/2025 12:10:28

soleno-therapeutics-says-aware-of-serious-adverse-event-in-fdas-faers-regarding-patient-who-died-case-reported-as-not-related-to-vykat-xr-treatment-patient-was-a-17-year-old-male-who-died-from-pulmonary-embolus-vykat-xr-has-proven-safety-and-efficacy-profile
Soleno Therapeutics Says Aware Of Serious ...
09/10/2025 16:40:31

-SEC Filing

Core News & Articles
10 Health Care Stocks Whale Activity In To...
09/09/2025 17:35:29

scorpion-capital-posts-on-x-that-it-remains-short-soleno-therapeutics
Scorpion Capital Posts On X That It Remain...
08/27/2025 15:59:11

https://x.com/ScorpionFund/status/1960731687903498571

guggenheim-reiterates-buy-on-soleno-therapeutics-maintains-106-price-target
Guggenheim Reiterates Buy on Soleno Therap...
08/27/2025 14:02:53

Guggenheim analyst Debjit Chattopadhyay reiterates Soleno Therapeutics (NASDAQ:SLNO) with a Buy and maintains $106 price tar...

wells-fargo-initiates-coverage-on-soleno-therapeutics-with-overweight-rating-announces-price-target-of-123
Wells Fargo Initiates Coverage On Soleno T...
08/20/2025 13:02:53

Wells Fargo analyst Derek Archila initiates coverage on Soleno Therapeutics (NASDAQ:SLNO) with a Overweight rating and annou...

scorpion-capital-posts-on-x-slno-soleno-therapeutics---mgmt-now-appears-to-be-copping-to-7-hospitalizations-per-guggenheim-flash-note-yesterday-if-the-hospitalizations-were-for-fluid-retention-and-potential-respiratoryheart-failure-its-hard-for-us-to-see-how-vykat-xr-has-a-viable-path-to-staying-on-the-market
Scorpion Capital Posts On X "$SLNO Soleno ...
08/19/2025 14:26:29

https://x.com/scorpionfund/status/1957809005222330512?s=46&t=dtUiyC3dUs5yGRgT9qYHWg

hc-wainwright--co-maintains-buy-on-soleno-therapeutics-raises-price-target-to-110
HC Wainwright & Co. Maintains Buy on Solen...
08/18/2025 11:03:39

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Soleno Therapeutics (NASDAQ:SLNO) with a Buy and raises the pri...

soleno-under-serious-scrutiny-as-short-seller-alleges-pws-drug-is-overpriced-unsafe
Soleno Under Serious Scrutiny As Short Sel...
08/15/2025 17:30:20

Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face ma...

guggenheim-maintains-buy-on-soleno-therapeutics-raises-price-target-to-106
Guggenheim Maintains Buy on Soleno Therape...
08/07/2025 14:15:12

Guggenheim analyst Debjit Chattopadhyay maintains Soleno Therapeutics (NASDAQ:SLNO) with a Buy and raises the price target f...

oppenheimer-maintains-outperform-on-soleno-therapeutics-raises-price-target-to-110
Oppenheimer Maintains Outperform on Soleno...
08/07/2025 13:29:35

Oppenheimer analyst Leland Gershell maintains Soleno Therapeutics (NASDAQ:SLNO) with a Outperform and raises the price targe...

soleno-therapeutics-q2-eps-009-beats-090-estimate
Soleno Therapeutics Q2 EPS $(0.09) Beats $...
08/06/2025 20:03:05

Soleno Therapeutics (NASDAQ:SLNO) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $...

Core News & Articles
Earnings Scheduled For August 6, 2025
08/06/2025 08:33:21

soleno-therapeuticss-earnings-a-preview
Soleno Therapeutics's Earnings: A Preview
08/05/2025 17:03:36

baird-maintains-outperform-on-soleno-therapeutics-raises-price-target-to-121
Baird Maintains Outperform on Soleno Thera...
07/11/2025 12:08:30

Baird analyst Brian Skorney maintains Soleno Therapeutics (NASDAQ:SLNO) with a Outperform and raises the price target from $...

soleno-therapeutics-prices-200m-public-offering-of-2352941-shares-at-85share
Soleno Therapeutics Prices $200M Public Of...
07/10/2025 13:08:47

Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment o...

soleno-therapeutics-reports-preliminary-q2-results-with-vykat-xr-net-revenue-between-31m33m-ends-quarter-with-2938m-in-cash
Soleno Therapeutics Reports Preliminary Q2...
07/10/2025 10:05:17

soleno-therapeutics-announces-two-presentations-featuring-data-on-vykat-xr-extended-release-tablets-in-prader-willi-syndrome-at-endo-2025
Soleno Therapeutics Announces Two Presenta...
07/01/2025 12:06:57

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION